S-1/A: Cortigent Files for IPO to Fund Vision and Stroke Recovery Tech

Cortigent, Inc. has filed an S-1/A amendment with the SEC, detailing its initial public offering to raise capital for its advanced neurostimulation technologies aimed at restoring vision and aiding stroke recovery.

Summary

• Cortigent, Inc. is pursuing an initial public offering (IPO) to raise capital for its neurostimulation technologies.
• The company is developing two primary systems: the Orion Visual Cortical Prosthesis System for artificial vision and a Stroke Recovery System to improve motor function in stroke patients.
• Cortigent's predecessor, Second Sight, previously marketed the Argus II retinal implant, which received FDA approval under a Humanitarian Device Exemption.
• The Orion system has received FDA Breakthrough Device designation and completed a six-year Early Feasibility Study (EFS) showing positive efficacy data.
• The Stroke Recovery System is in earlier development, with plans for an Early Feasibility Study and a potential reapplication for Breakthrough Device designation.
• The company anticipates needing substantial additional capital to fund clinical trials and commercialization efforts.
• Cortigent plans to use the IPO proceeds for research and development, manufacturing for clinical studies, and to repay amounts owed to its parent company, Vivani Medical, Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's pre-revenue status, ongoing losses, going concern doubts, and the significant risks associated with medical device development and regulatory approval.

Positives

• Cortigent has a history in neurostimulation technology, with its predecessor having an FDA-approved product (Argus II).
• The Orion Visual Cortical Prosthesis System has received FDA Breakthrough Device designation, potentially accelerating its path to market.
• Early feasibility study data for Orion shows subjects performed significantly better with the system on versus off in key visual function measures.
• The company has a robust intellectual property portfolio with 147 issued U.S. patents and 11 issued European patents.
• The addressable market for Orion is estimated at 82,000 Americans, with a potential market size of $4 billion.
• The Stroke Recovery System targets a large market of stroke victims, with an estimated addressable market of 195,000 U.S. victims annually and a potential market size of $6 billion.
• The company has a clear plan for clinical trials, with a pivotal trial for Orion expected to commence in late 2027 and for the Stroke Recovery System in early 2029.

Negatives

• Cortigent is a pre-revenue company with a history of operating losses and expects these losses to continue.
• The company's financial statements indicate substantial doubt about its ability to continue as a going concern.
• The company will require substantial additional capital, and there is no guarantee it will be available on favorable terms.
• The development and regulatory approval process for medical devices is lengthy, expensive, and uncertain.
• Three subjects in the Orion EFS requested device explantation for reasons unrelated to the device's efficacy or safety, limiting long-term data.
• The FDA denied Breakthrough Device designation for the Stroke Recovery System in June 2023, which could lead to slower FDA interactions.
• The company has no large-scale manufacturing experience, which could limit growth.
• Vivani Medical, Inc. will remain the controlling shareholder (approximately 77%) after the IPO, potentially limiting independent shareholder influence.

Risks

• Cortigent currently has no commercial products or product revenue and may never become profitable.
• The company's commercial success depends on market acceptance of its future products, which is not guaranteed.
• Competition from major medical device companies and other institutions could hinder development and commercialization.
• Clinical trial results may not be predictive of future outcomes, and there's a risk of failure to demonstrate safety and efficacy.
• Failure to obtain regulatory approvals or secure favorable product reimbursement could significantly impact sales potential.
• The company is dependent on suppliers for critical materials, and disruptions could delay development.
• Intellectual property protection is crucial, and challenges to patents or infringement claims could adversely affect the business.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• The company may not be able to obtain additional capital on favorable terms, potentially restricting operations.
• The price of common stock may be volatile, and the value of an investment could decline.
• The company is subject to stringent domestic and foreign medical device regulations, and unfavorable regulatory actions could have a material adverse effect.

Future Outlook

Cortigent anticipates needing substantial additional capital to fund its clinical trials and commercialization efforts for both the Orion Visual Cortical Prosthesis System and the Stroke Recovery System. The company expects to continue incurring operating losses for the foreseeable future.

Management Comments

• "We believe that our 20-year history in developing neurostimulation for artificial vision with the Argus II system positions us well for expanded neurostimulation applications such as Orion and the stroke recovery system."
• "No assurance can be made that clinical trials will demonstrate safety and efficacy or will lead to commercial products."
• "We believe that our 60-channel cortical stimulation device has the potential to target neuron populations more precisely and generate favorable clinical results."
• "The development process may take longer and be more costly than anticipated and we may not achieve reimbursement levels similar to the one we received for our Argus II device or obtain other suitable reimbursement levels that we may require."

Industry Context

StockSavvy.ai notes that Cortigent operates in the highly competitive and rapidly evolving medical device industry, specifically in the field of neurostimulation. The company's focus on restoring vision and motor function through implantable devices places it at the forefront of advanced medical technology, competing with both established players and innovative startups.

Corporate Governance

Legal Proceedings

• Cortigent is not currently party to any material legal proceedings.
• The company may be involved in legal proceedings or subject to claims incident to the ordinary course of business, which could have an adverse impact due to defense and settlement costs.

Related Party Transactions

• Cortigent was formed by Vivani Medical, Inc., its parent company, which contributed Second Sight's neurostimulation assets to Cortigent.
• Vivani has provided funding and services to Cortigent under a Transition Funding, Support and Services Agreement, with repayment obligations outlined.
• Vivani will remain the controlling shareholder after the IPO, with the ability to influence corporate matters.

Stakeholder Impact

• Shareholders: Potential for dilution due to future capital raises, volatility in stock price, and limited influence due to controlling shareholder.
• Employees: Potential for growth and equity ownership opportunities, but also risks associated with a pre-revenue company.
• Creditors: The company's going concern status and need for financing may impact its ability to meet obligations.
• Customers (future): Potential beneficiaries of vision restoration and stroke recovery technologies, but subject to regulatory approvals and market acceptance.

Next Steps

• Complete the IPO to secure necessary funding.
• Manufacture and validate new Orion devices for a planned pivotal clinical trial.
• Commence the Orion pivotal clinical trial in late 2027.
• Conduct a Stroke Early Feasibility Study (Stroke EFS) in parallel with Orion device manufacturing.
• Plan and commence a pivotal clinical trial for the Stroke Recovery System in early 2029.
• Work with the FDA to gain agreement on additional clinical studies required for marketing approval of Orion and the Stroke Recovery System.
• Reapply for Breakthrough Device designation for the Stroke Recovery System once clinical data is available.

Key Dates

Recommendation

While Cortigent possesses promising neurostimulation technology with significant market potential and FDA Breakthrough Device designation for Orion, the company is pre-revenue, faces substantial financial risks including a going concern doubt, and has a lengthy, uncertain regulatory and clinical development path. The dependence on future financing and the controlling shareholder structure also present risks. Therefore, a 'hold' recommendation is appropriate, suggesting investors monitor clinical trial progress, regulatory approvals, and future financing rounds before considering a more aggressive stance.

Keywords

Cortigent, IPO, S-1/A, Neurostimulation, Artificial Vision, Orion, Stroke Recovery, Medical Device, FDA, Breakthrough Device, Clinical Trials, Vivani Medical